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Zusammenfassung
Die Prävalenz von durch multiresistente Erreger (MRE) verursachten
nosokomialen Infektionen ist innerhalb der letzten Dekade signifikant
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Im Ergebnis wurde eine große Bandbreite verschiedener Antworten er-
halten.Esstelltesichheraus,dassdieMRSAPrävalenzinallenLändern
ein wachsendes Problem darstellt, wenn auch weniger stark in den 10 ClinicalInstituteforHygiene
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Präventionsstrategien und ein in kurzer Zeit Ergebnisse lieferndes
Screening z.B. mittels PCR in einem vereinten und expandierenden
Europa von herausragender Bedeutung sind. Eine mögliche Strategie
zur Verbesserung der Infektionskontrolle könnte darin bestehen, dass
die Gesundheitsversicherungen nur Verträge mit den Krankenhäusern
abschließen, die ein funktionierendes Infektionsmanagement imple-
mentiert haben.
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Introduction
The prevalence of health-care associated infections
caused by multi-drug resistant organisms, including
Methicillin-resistantStaphylococcusaureus(MRSA),has
significantly increased over the past decade [1], [2], [3].
The trend is visible in all European countries, albeit less
stronginTheNetherlands,Slovenia,France,Austria,and
Scandinavia [1]. Prevention strategies in the European
Communitywillbecomeofimportance,includingharmon-
ization of typing methods [4]. Because of consequences
for patients as well as increasing costs due to prolonged
stayfollowingMRSAinfections,thissituationwilldamage
the European health-care systems [5].
In view of this development, a workshop was initiated at
the 8
th Congress of the German Society of Hospital Hy-
giene (DGKH) held in Berlin in 2006. The aim of this
workshopwastogiveanoverviewofthecurrentsituation
ofMRSAinEuropeancountriesandJapanandtoprovide
potentialstrategiesinfuturepreventionofMRSAdissem-
ination. The workshop was a reaction to a document of
the European commission under the auspices of the
“health and consumer protection directorate-general”
outlined in an open consultation in December 2005 en-
titled “Public consultation on strategies for improving
patients’ safety by prevention and control of health-care
associatedinfections”.Thisdocumentstatesthat“Health-
careassociatedinfectionsaffectanestimatedoneinten
patients and lead to considerable increase of illness,
mortalityandcosts.Theseinfectionsarenotconstrained
by national boundaries and can rapidly spread between
countriesasevidencedbyinternationalspreadofMRSA”.
The reason why MRSA explicitly was mentioned gives an
additionalimpulsetogenerateanoverviewofthevarious
strategies on its control and prevention.
During the workshop, participants representing clinical
microbiologists and leading experts of their respective
countries presented and discussed issues pertaining to
MRSA such as screening, laboratory diagnostic with par-
ticular emphasis on more rapid diagnostic approaches
likeapplicationofchrome-agarplatesandthePCRassay
technique [6], isolation precautions, decolonisation,
burden for the individual patient and society, and the
emerge of community-associated MRSA.
Finally, a questionnaire encompassing 20 questions ad-
dressing topics such as epidemiology, current strategy
measures and future prospects was distributed to the
participants. The aim of this paper is to summarize the
current overall strategies and measures in preventing
and controlling the spread of MRSA on the individual
country level, to highlight similarities and to discuss
country specific variations in order to generate a basis
for a future harmonisation in a European perspective.
Materials and methods
The 8
th International Congress of the DGKH was held in
Berlin from in April 2
nd to April 5
th 2006. During the con-
gress, a separate workshop on European MRSA preven-
tion and control strategies was held. After the MRSA
workshop, participants (see authors’ list) representing
12EuropeancountriesandJapancompletedastructured
questionnaire consisting of 20 questions on MRSA in
their respective countries. Representatives from the fol-
lowing countries in alphabetic order responded to the
questionnaire: Austria (A), Germany (D), Hungary (HU),
Italy (IT), Japan (JP), France (FR), Spain (ES), The Nether-
lands(NL),andtheScandinaviancountriesDenmark/Fin-
land/Sweden/Norge/Island (DK/FI/SE/NO/IS) as a joint
group.
Forfurtherbackgroundinformation,literaturereferences
and other sources have been used for the respective
countries. The reference literature for the individual
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[12], [13], [14], [15], [16], [17], [18], [19], DK/FI/SE/
NO/IS: [20], [21], [22], [23], [24], [25] [26], ES: [27],
[28], [29], [30], [31], [32], [33], [34], [35], FR: [36], [37],
[38], [39], [40], HU: [41], [42], [43], IT: [44], [45], [46],
[47], [48], [49], JP: [50], [51], [52], [53], [54], [55], [56],
[57], [58], NL: [6], [59], [60], [61], [62], [63], [64], [65].
Results
Below, the questions together with the participants’ an-
swers are summarised.
Q1ArethereNationalGuidelinesforpreventionofMRSA
disseminationand/orinfection?Ifnot,aretheseregional
guidelinesforpreventionofMRSAdisseminationand/or
infection?
Representatives of 9 European countries stated that
GuidelinesforMRSApreventionareavailableatanational
level. In Germany, recommendations for prevention and
control of MRSA in hospitals and other medical institu-
tionsarepreparedbytheCommissionofHospitalHygiene
and Infection Prevention at the Robert Koch-Institute
(RKI). For DK/FI/SE/NO/IS, national guidelines are
available in all countries with regional applications in
most acute care hospitals. In France, the Comité Tech-
nique National des Infections Nosocomiales (Guide pre-
vention des BMR) prepared national Guidelines, and
Hungary and the Netherlands also have national
guidelines for prevention of MRSA. For Japan, Austria,
Spain and Italy so far, no national guidelines exist. While
Spain follows adaptation of the Centers for Disease
Control and Prevention recommendations, Italy has re-
commendationsproducedby“SIMPIOS”,amultidisciplin-
ary scientific society for prevention of healthcare related
infections. In Austria there is no single official national
recommendation for prevention and control of MRSA in
hospitals and health-care settings, but there are specific
recommendations within the 9 Austrian federal states,
mostlyinlinewiththeGermanrecommendationsprovided
by the Commission of Hospital Hygiene and Infection
Prevention at the RKI.
Q2ArethereNationalguidelinesforlaboratorydiagnosis
and susceptibility testing of MRSA? If not, are these dif-
ferentlocalorregionalguidelinesforlaboratorydiagnosis
and susceptibility testing of MRSA?
Only France (Recommandations méthodologiques pour
la surveillance de la résistance aux antibiotiques dans
les labos de microbiologie), Italy and Japan and the
Scandinavian countries stated that they have specific
national recommendations for susceptibility testing of
MRSA. In Italy, the testing recommendation has been
produced by the antibiotic committee of AMCLI, the Clin-
icalMicrobiologySociety,aswellasbyISS(NationalInsti-
tute of Health) for the laboratories participating to Pro-
getto “AR-ISS” (Antibiotic Resistance Network of the
HealthInstitute)ontheinternet(http://www.simi.iss.it/).
However, the recommended methods and breakpoints
generallyfollowtheClinicalLaboratoryStandardsInstitute
(CLSI) recommendations. In Japan, breakpoints for
Staphylococcus aureus are defined as MIC of oxacillin in
Mueller-Hinton Broth with is 4 µg/ml or more. Most
laboratories in Austria, Germany, Spain and Hungary fol-
low CLSI recommendations.
Q3 Presentation of development of MRSA prevalence in
the last 10 years.
For Italy and Japan, no sufficient data on MRSA preva-
lence are available, although some selected point-
prevalencestudieshavebeenconducted[48],[49],[50],
[51], [58]. While DK/FI/SE/NO/IS, The Netherlands,
Spain, Hungary and Germany (Data from Paul-Ehrlich-
Society and European Antibiotic Research Study Surveil-
lance (EARSS), available at http://www.rivm.nl/earss/)
report gradual to drastic increases over the past years,
the last French national prevalence survey (June 2006)
evidenced a moderate decrease of MRSA prevalence
confirmedbythemicrobiologicallabincidencedata.Data
from Austria (EARSS) indicates a gradual increase over
the last decade. Recently, however, a moderate trend
towards decrease in MRSA and increase of other multi-
drugresistantpathogens,especiallyESBL,isobservable.
Q4IsthereinformationaboutnationalorregionalMRSA
outbreaks?
With exception for France, where only major outbreaks
are reported, most countries have information on out-
breaks, though to various levels. In Austria, outbreaks of
only clinical relevant infections are monitored. The data
are collected and monitored by the Austrian National
Surveillance System ANISS. Similarly in Italy, a regional
surveillancesystemhasbeendevelopedbyregionEmilia
Romagna.InGermanyandHungary,notificationofMRSA
infection outbreaks to the local public-health service is
mandatory. In The Netherlands outbreaks are monitored
through the National Institute of Health and the Environ-
ment and also in newspapers and medical journals. For
DK/FI/SE/NO/IS, major outbreaks are communicated
via the National Institute for infection diseases control in
the respective country but also through informal canals
within the country, but generally not between the coun-
tries.
Q5 How often do re-admissions of already known colon-
ised MRSA patients in the same hospital occur?
In none of the countries re-admission of known MRSA
positive patients is monitored. Therefore no detailed in-
formation is available. In Germany, also no data are
available; however, some information was compiled by
Chaberny et al. [12]. For The Netherlands, based on pre-
valenceelectronicmarkingandfollow-upofpatientsafter
discharge,itcanbestatedthatsuchre-admissionsoccur
regularly; however, detailed data also is not available.
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screening in general or is this restricted to certain risk
groups, and if so, which risk groups?
The respondents answer this question heterogenic. Only
in Spain, there is no general recommendation for MRSA
screening. In Austria, following patients at risk are
screened on admission: previous known MRSA-infec-
ted/colonised patients, patients with frequent re-admis-
sions, with chronic wounds, with catheters (urinary tract,
vascularcatheters),andpatientswithahistoryofprevious
long-term antibiotic therapy. Additionally, depending on
thelocalepidemiologicsituation,selectedhospitalscreen
patientsfromlong-termhealth-carefacilities.Intheevent
of suspected outbreak, patients and staff are screened
as well. In Germany, following risk groups are screened:
patients with proven MRSA colonisation/infection, from
high prevalence regions or institutions, with contact to
MRSA-colonized/infectedpatients,orwithatleasttwoof
thefollowingriskfactors:nursinghomes,devices,dialysis,
wounds, burn injury, and working in pig farms. Other risk
groupsdependontheepidemiologicalsituation.Similarly,
in DK/FI/SE/NO/IS, following patients are screened on
admission: previous MRSA-infected/colonised patients
on admission. In most countries there is no time limit
especiallyinapatientwithriskfactors.Patientshospital-
isedovernightorundergoneinvasiveprocedures/worked
abroadwithin6months(1year)especiallyoutsideNordic
countries,hospitalisedinaNordichospitalwithinaregion
with ongoing MRSA outbreaks, and patients from Long-
term care facilities (LTCF). France: screening is recom-
mended for all patients in intensive care, from LTCF and
patients transferred from other health-care facilities. In
Hungary, patients are screened if the admission history
indicatesMRSA,previousantibiotictherapyandifpatients
weretransferredfromanotherhealth-carefacilityorunits
suspected to have MRSA. Italy: It is recommended that
all patients admitted to ICU’s should be screened. Pa-
tientsadmittedforsolidorganorbonemarrowtransplant-
ation, heart surgery or renal dialysis are usually also
screened. In Japan, active screening is restricted to car-
diac surgery and haematological patient, but not recom-
mended officially. In The Netherlands, all patients from
aforeignhospitalaregenerallyscreenedforMRSA.Some
hospitals screen patients admitted to the intensive care.
Previously known MRSA carriers are screened.
Q7 Set-up of the MRSA screening: a) What anatomic
locations are sampled? b) How often is this sampling, if
more than once, is there a time interval? c) What is the
method of specimen collection?
Whileallparticipantsstatedthatthemethodofsampling
is using a swab, the time interval for screening ranged
from once to twice weekly. In all countries, the nostrils
areinvestigatedforMRSA.Inmostcountries,additionally
wounds and catheter incision site are also sampled, if
present,orurineincaseswithlong-termurinarycatheters.
Q8 Recommended laboratory diagnostic methods: a)
agarmedia,b)enrichmentbroth,c)selectiveagarmedia,
such as oxacillin-resistant S. aureus screening agar
(ORSA) and other “chromagar’s”, d) bacterial species
determination and sensitivity testing by disc screening
by oxacillin and/or other discs MIC by E-test, e) Is vanco-
mycin sensitivity determined?, f) rapid tests e.g. MRSA
latex screen, genetic determination, PCR, g) indications
for typing participation in European databases.
In Austria, Spain, and The Netherlands, the standard
laboratorydiagnosticmethodfordetectingMRSAisusing
a selective medium together with enrichment broth.
However,othermethodsareusedadditionallyasrequired.
In Germany, different agar-media and increasingly PCR
techniques together with cultural confirmation are used.
DK/FI/SE/NO/IS use agar-medium, approximately 50%
used additionally enrichment broth, and 50% selective
agar (ORSA, or with cefoxitin). As in Germany, there is an
increasing tendency to use PCR methods for screening
with cultural confirmation. In Hungary, mostly blood-agar
and cooked meat bouillons are used; some also use se-
lective media like ORSA, which most laboratories do in
Italy. In Japan, mostly Mannitol-egg salt agar is used in
various combinations with chrome-agars and ORSA. In
all countries, vancomycin sensitivity is determined. With
theexceptionofJapan,allcountriesparticipateatEARSS.
Q9 Isolation precautions: a) generally, no isolation or
onlybarrierprecautions,b)preventiveisolationbyadmis-
sion in the hospital (always or only with risk patients
such as patients in intensive care units and/or selected
wards), c) isolation after detection of MRSA, d) indica-
tions to end the isolation precautions.
With exception of Italy, in all countries MRSA-positive
patientsareisolatedinasingleroom,ifpossible.Addition-
ally, in DK/FI/SE/NO/IS, France, Hungary, The Nether-
lands, and selected hospitals in Germany, high risk pa-
tients are isolated until their MRSA status is known in
course of admission screening.
MRSA isolation is discontinued, if 2 negative swabs
within 2 days (Austria), or 3 negative swabs within 3 days
(Germany), or 3 negative swabs within 7 days (The
Netherlands) are obtained. For all other countries with
exception of Italy, isolation is stopped based on not fur-
ther specified algorithms indicating that a patient is
MRSA-negative.
Q10 Overall decontamination prescription: a) nose:
– decolonisation treatment of choice, duration of treat-
ment, post-decolonisation control, b) throat: – decolon-
isationtreatmentofchoice,durationoftreatment,post-
decolonisation control, c) wounds: – decolonisation
treatment of choice, duration of treatment, post-decol-
onisation control, d) body, hair: – decolonisation treat-
ment of choice, duration of treatment, post-decolonisa-
tioncontrol,e)tracheostoma:–decolonisationtreatment
of choice, duration of treatment, post-decolonisation
control, f) gastrointestinal tract: – decolonisation treat-
ment of choice, duration of treatment, post-decolonisa-
tioncontrol,g)arefollow-upproceduresofthedecontam-
ination prescription embedded to investigate whether
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same, a combination answer will be procured.
For MRSA nasal-carriage eradication, most countries in-
cluding Austria use mupirocin ointment 3x daily for 3–5
days(inGermanysomealsouseoctenidine[66])together
with antiseptic mouth wash 3x daily with chlorhexidine,
octenidineorpolihexanideandtotalbodywashoncedaily
withchlorhexidine,octenidine,polihexanideorpovidone-
iodine. In Japan, additionally a povidon-codine gargle is
used.
InFrance,Italy,andDK/FI/SE/NO/ISsuccessoferadica-
tionisnotconfirmedgenerally,patients’follow-upoccurs
according to doctor’s order. In Germany, control of
eradicationisroutinelydoneinhealth-careworkers(after
10 days, 1 month, 3 months) and in patients on 3 days
starting on the third day after end of decontamination.
In all other countries, eradication success is monitored
after 24 (Spain) to 48 hours after last application of anti-
microbial compounds.
Q11Methodsforbarrierprecautionstopreventre-colon-
isation: a) area to be involved in the preventive isolation
measures,b)bedhygiene,c)disinfectionofthesurround-
ings of the patients, d) management of private belong-
ings of the patients, e) handling of kitchen utensils and
soiled linen, f) handling of instruments to be used for
diagnostic or therapeutic procedures after MRSA con-
tamination.
A: a–f is applied. No special handling of kitchen utensils
is performed other than routine hospital standard. D: a.
private room, b. daily change of linen, c. bedstead, bed-
side locker, bath, hand contact areas, d. exchange or
disinfectionofpersonalitems(glasses,razor,toothbrush
etc.), e. no special procedures for kitchen utensils, disin-
fecting washing of linen, f. disinfection after use.
DK/FI/SE/NO/IS: Since MRSA patients are cared for
isolation with strict precautions this is not an issue. ES:
a, b and f are applied. FR: a–f is applied. HU: a and f.
Precautions to prevent re-colonisation are applied. Isola-
tion measures are standard contact and droplet precau-
tions. IT: Bed hygiene, disinfection of the surroundings
of the patient and dedicated instruments, such as
thermometers and stethoscope. JP: Usually cleaning of
the patient environment only. NL: MRSA patients are
cared for in strict isolation. Masks and caps and a long-
sleeved coat with cuffs should be worn while treating a
patient in strict isolation.
Q12 Education of personnel involved in different fields
of patient management, cure and care e.g. medical
doctors, nursing staff, physiotherapeutic and radiology
staff, cleaning and disinfection household staff.
In all countries, continues medical education on MRSA
is provided. Education contains information regarding
epidemiology of MRSA-spread and specific precautions.
For DK/FI/SE/NO/IS, it was stated that generally the in-
fection control practitioner is consulted when infected
patients are cared for.
Q13Arethereguidelinesinthecure,careorsocialinter-
actionswithMRSApositivepatientsafterdischargefrom
the hospital also in relation to decolonisation schedules
for the: a) outpatient clinic in or outside the hospital, b)
nursing care at home, c) in nursing homes, d) for senior
citizens, e) other public health situations anticipated
(sports, clusters of PVC + strains).
In most countries, no explicit patient or population infor-
mation exists. In all countries, selected hospitals and
nursing homes provide general information on MRSA. In
Germany, the RKI prepared information on Staphylococ-
cus aureus and Guidelines for Infection Prevention in
geriatric care and nursing homes. For DK/FI/SE/NO/IS
guidelines for LTCF exist in most countries. In The Neth-
erlands, the Working Group on Infection Prevention has
prepared some information for setting outside the hos-
pital.
Q14Arethesedecolonisationschedulesafterdischarge
from the hospital reimbursed? Is carriage of MRSA
registered so that at re-admission at the hospital the
patients can be identified as a MRSA carrier?
In none of the countries complete MRSA eradication
outside of the hospital is reimbursed. Also, none of the
countries has a system in place where the MRSA status
of a patient is registered uniformly in order to identify
these patients at re-admission. Some selected hospitals
have installed an electronic registration system, which
gives 'warning' at admission of previously MRSA-positive
patient. Many hospitals actively ask for previous MRSA
carriage and hospitalisation abroad on admission. In
Germany, mupirocin is reimbursed. Only in Italy MRSA
eradication is reimbursed outside the hospital.
Q15Aretherenationalrecommendationsforappropriate
selection and use of antibiotics supporting to prevent
selection and dissemination of MRSA?
With exception of Italy, all countries have recommenda-
tions on selection and use of antibiotics. In Austria (ABS
program), these recommendations are prepared by the
antibiotic strategy platform implemented by the Austrian
Ministry for Health, Social affaires and youth. In The
Netherlands and DK/FI/SE/NO/IS national antibiotic
formulary is present. In Germany, Japan and Hungary re-
commendations are provided by medical societies.
Q16 a) Is there an obligating participation in national
surveillancesurveys?Isthisrelatedtothesubject,listed
as (question 1), b) Is vancomycin resistance included in
this surveillance?
Only in Germany and DK/FI/SE/NO/IS participation in
national surveillance is obligatory, including surveillance
of vancomycin resistance. In Germany, participation is
specifically regulated by §23 of the German Infection
Protection Law (Infektionsschutzgesetz). In Spain and
Japan, mandatory MRSA surveillance exists. In all other
countries,surveillanceisnotmandatory,butencouraged
and voluntary, and is largely followed. If surveillance oc-
curs, vancomycin resistance also is reported.
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ity/government for outbreaks of MRSA?
WithexceptionofAustriaandSpain,inallothercountries
notificationofMRSAoutbreaksismandatory.InGermany
and The Netherlands, notification is regulated by law (§6
of the German Infection Protection Law and Law of infec-
tiousdiseases,respectively).InDK/FI/SE/NO/ISreporting
of MRSA outbreaks is not mandatory, however, health
authorities will notice since reporting of all MRSA cases
is mandatory. In Italy, although notification is required by
law, MRSA outbreaks rarely are reported.
Q18 What is the impact of community-acquired (CA)
MRSA?
In all countries, only little data is available and mostly
because of the low number of reports quality of data is
not sufficient to interpretated meaningful trends. How-
ever,sporadicnotificationsindicatepotentialforincrease.
In DK/FI/SE/NO/IS where reporting of all MRSA cases
includingMRSAcarriageismandatory,CA-MRSAisviewed
asacomingthreatwithanincreasingnumberofdomestic
casesthelast3–5years.ThereisalsoanincreaseofCA-
MRSA acquired abroad during vacations. Also, in Spain,
France and The Netherlands the incidence seems to be
increasing, particularly Panton-Valentine Leucocidine
(PVL) positive strains. Only in Japan it s reported that
there seems to be no specific issue with community-ac-
quired MRSA so far (H. Kobayashi, personal communica-
tion).
Q19 What are the three main future expected develop-
ments in MRSA?
ParticipantsstatethatifMRSAincidenceandprevalence
continue to increase, there is the risk that a decrease of
medical awareness might occur as no significant break-
through is achieved. Further dissemination, increase of
infections, and increase of CA-MRSA is expected. MRSA
might become a public indicator for quality and surveil-
lance results on the individual hospital level, as occurred
in France now. In DK/FI/SE/NO/IS it is expected that
MRSA in the community might increase and will spread
within certain risk groups. Also, MRSA might spread to
thecommunityandLTCFs,andbacktohospitals,resulting
inanincreasingnumbersofoutbreaksinhospitals.Spain
will focus on increase control of carriers and alternative
treatments.Hungarywillputemphasisonreviewandup-
dateofnationalguidelinesofMRSAprevention,integrate
preventionintonursing-care,andimplementamandatory
reportingofMRSAinfectionstotheHungarianNosocomial
Surveillance System, together with regulation for appro-
priate use of antimicrobials. Italy also will stress more on
the development of surveillance systems on a national,
regional, and local level, place greater attention to hand
and environmental hygiene, measures to prevent trans-
mission of MRSA and other multiple-resistant organisms
and to antibiotic use. In addition, implementation of
measuresdevotedtopreventspreadofresistanceoutside
the hospitals are needed. For Japan it is foreseen that
MRSA becomes a “normal” resident of the populations’
microbial flora, virulent strains will emerge, and an in-
crease of VRSA and other multi-drug resistant MRSA is
expected.Similarly,TheNetherlandsexpectsemergence
ofvancomycinintermediateresistantstrains,andhidden
community spread, including PVL + strains. The strategy
will be more extensive screening to keep the search and
destroy policy ongoing, together with rapid, e.g. PCR,
diagnosis.
Q20 Are there important MRSA topics worth to be re-
viewed concisely, which were outside the scope of the
above presented findings?
Participantsstatethatinviewoftheincreasingmupirocin
resistancethereisaneedforevidencebasedalternatives
for MRSA eradication. Also, the role of regional networks
in MRSA-prevention and control needs to be reviewed.
Results of other national surveillance of multi-resistant
organismsneedtobepooled,suchasglycopeptideresist-
ant enterococci and multiresistant Enterobacteriaceae
including those with ESBL, in order to identify robust
universalstrategiesforcontrol.Japanwouldbeinterested
in issues of transportation of virulent and multi-drug re-
sistantMRSAstrains.InTheNetherlands,newchallenges
willbefollow-upevents,community-acquiredPVLpositive
strainsinclusters,animalreservoirs(e.g.pigs),unexpect-
ed events, and more rapid diagnostic approaches such
as the use of PCR or application of rapid growth chrom-
agar media.
Matters such as reimbursing costs for MRSA screening,
even before hospital admission and reimbursement of
costs generated in course of eradication in the hospital
and outpatient settings need to be solved. In countries
usingaDRG-basedfinancemodel,thiscouldbeachieved
by taking these costs into the DRG-reimbursement
scheme. Aside of cost issues, it would be supportive to
introduce also a laboratory-based reporting system for
MRSA together with a better and more uniform docu-
mentationconceptofprescribedantibiotics.Apotentially
high impact concept of improving infection prevention
andcontrolmeasuresgenerallycouldbetherequirement
of health insurance providers only to sign contracts with
hospitals, which can proof having a structured and well
organised infection control and quality management
system in place.
Discussion
MRSA has been extensively reported in some countries
(e.g. Scandinavia, The Netherlands) and published in in-
ternational journals, while findings from other countries
(e.g. Japan, Hungary) remain largely available in national
surveys and publications in the respective mother lan-
guage.
The responses to the questions of this survey allow out-
lining some trends. National guidelines are not generally
present.Therearesomerecommendationsforcontrolling
MRSA, but they vary in structure and content. The in-
crease of MRSA has been noted nearly everywhere but
6/10 GMS Krankenhaushygiene interdisziplinär 2010, Vol. 5(1), ISSN 1863-5245
Kramer et al.: Epidemiology of MRSA and current strategies in Europe ...the different incidences between countries might be in-
fluenced by the strategy of the various health-care set-
tings. The epidemiology of MRSA is generally surveilled.
Unnoticed re-admissions of known MRSA carriers can
easily occur due to the absence of effective screening
policies [64]. When patients are screened, a variety of
different anatomic locations are sampled. Enrichment
culture to obtain a maximal yield has been advocated.
Decolonization procedures are often applied, but these
measuresaremostlynotreimbursed.Isolationmeasures
varywidely.Ingeneral,specificeducationonMRSAissues
is provided for relevant personnel. The increase of PVL
positive community-acquired MRSA has been noted
generally. Future developments and new threats are
spotted in this field, including “vancomycin resistance”,
PVL positive community-acquired strains “surprising
findings” (e.g. pigs), further spread of MRSA in commu-
nities and hospitals, and the need for rapid detection
techniques.
Analysing all different answers and views, it becomes
evidentthatcountermeasuresagainstMRSAvarystrongly
between countries. Strategies range from active “search
anddestroy”toanattitudeof“letitgo”.Ifstrategyagainst
MRSA are loosened, an increased prevalence of MRSA
is to be expected, leading to more extended health-care
costs. It is no coincidence that in countries without strict
controlmeasuresthehighestprevalenceofMRSAoccurs.
Yet, this is not a universal rule. In high-prevalence re-
gion’s,ithasbeendemonstratedthatinfectionprevention
measures specifically directed against MRSA (isolation,
better hand hygiene, disinfection of the surroundings of
patients) are of benefit in reducing the burden of MRSA
and associated costs, without the expectation of ever be
able to reach the aim of a “search and destroy” policy,
or “zero MRSA level”. The recent success obtained in
Francewithanincidencereductionof30%withinthelast
ten years is an example highlighted by EARSS. Today, not
only in these countries, but also in countries who apply
“search and destroy” policy successfully, such as The
Netherlands and the Scandinavian countries, this aim is
threatened and possibly sabotaged by the rise of com-
munity acquired, PVL positive strains family transmitted
MRSAandanimal(e.g.pigs)[15],[65]facilitatedspread,
including partly different MRSA types than the usual
predominant MRSA clones. Developments outside of the
hospital are a direct threat for unexpected (re)-introduc-
tion of MRSA into the hospital. Nevertheless the recent
published agreements of the Public Health-care Council
of The Netherlands to maintain the strict search and
destroy policy stated: “The most important argument for
maintaining this strategy is that rescinding the policy will
lead to a much higher prevalence of MRSA and the asso-
ciated increase in disease burden and mortality”. British
research has shown that rescinding a strict policy results
in a marked increase in MRSA infections. Moreover, if
the policy were to be rescinded, the costs incurred by
MRSA infections would strongly increase and would
probably be much higher than in the current situation
with the strict MRSA policy.
Costs for decolonisation of patients and health-care
workersandgeneralcontrolmeasuresagainstMRSAare
often not reimbursed, yet, they are easily justifiable. Pre-
ventivemeasuresagainstMRSAshouldberegardedequal
withvaccination.Thisalsoshouldincludelaboratorycosts
for detection and follow-up screening [64]. To underline
the importance of MRSA, it should become a notifiable
organism, as it is the case in the United Kingdom [2], [3]
and Scandinavia.
General principles like early detection and isolation of
MRSA positive patients are recommended by all
guidelines[67].Yet,thereisstillaroleforconsensusand
theopinionofexpertsindevisingnationalguidelines.We
consider the summary of the workshop on MRSA hold in
Berlin as an addition to detailed and useful compilation
of Humphreys review [67] on national guidelines, which
predominantly focused on English speaking countries,
although Germany and The Netherlands were included.
Despite increasing knowledge, more rapid detection
techniques, including PCR [6], and interventions with re-
gard to the multi-resistant strains problem and optimal
treatment of infection-diseased patients worldwide, the
trends in recent years show that the future pertaining to
MRSA is not viewed optimistically by various experts in
the field.
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